Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Background: Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic settings, including for parenchymal brain metastases, their efficacy for patients with LM has no...

Full description

Bibliographic Details
Main Authors: Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Amelie Darlix, Ivica Ratosa, Emanuela Ferraro, Gaia Griguolo, Valentina Guarneri, Alessia Pellerino, Silvia Hofer, William Jacot, Hans-Joachim Stemmler, Marcel P.H. van den Broek, Nika Dobnikar, Francois Panet, Zubin Lahijanian, Aki Morikawa, Andrew D. Seidman, Riccardo Soffietti, Lawrence Panasci, Kevin Petrecca, April A.N. Rose, Nathaniel Bouganim, Matthew Dankner
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Breast
Subjects:
Breast cancer
Leptomeningeal
Intrathecal
Trastuzumab
Deruxtecan
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977623004502

Internet

http://www.sciencedirect.com/science/article/pii/S0960977623004502

Similar Items